SCHEMBL5727243

SCHEMBL5727243

O=C(c1ccccc1)c1cccc(OC2CCCCO2)c1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.46
NPC1 O15118 2/20 0.45
STS P08842 1/20 0.45
RAB9A P51151 2/20 0.45
HRH3 Q9Y5N1 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DHFR P00374 1/20 0.43
POLB P06746 1/20 0.43
ELANE P08246 1/20 0.43
GAA P10253 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD11B1 P28845 1/20 0.42
KAT6A Q92794 1/20 0.42
ABCB1 P08183 1/20 0.41
SRD5A2 P31213 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4827698 0.88 KMT2A (0.48) PKMNPC1RAB9ADHFRMEN1
SCHEMBL11767308 0.88 ELANE (0.52) NPC1STSRAB9APOLBELANE
SCHEMBL3058714 0.85 ALDH1A1 (0.46) PKMNPC1RAB9ATDP1DHFR
SCHEMBL1763723 0.83 KMT2A (0.57) PKMRAB9AHRH3L3MBTL1POLB
SCHEMBL25621200 0.83 HPGD (0.47) PKMNPC1RAB9AL3MBTL1DHFR
SCHEMBL11769348 0.83 HDAC6 (0.45) PKMDHFRMEN1KMT2AHSD11B1
SCHEMBL9637065 0.83 DHFR (0.45) PKMRAB9ADHFRMEN1KMT2A
SCHEMBL5619081 0.82 MAOB (0.56) NPC1RAB9ATDP1MEN1KMT2A
SCHEMBL5619084 0.82 MAOB (0.56) NPC1RAB9ATDP1MEN1KMT2A
SCHEMBL10830967 0.82 DHFR (0.49) PKMNPC1RAB9ADHFRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1705169-A2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators Hormos Medical Ltd. (FI) 2006-09-27 EP disclosed
EP-1235776-B1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORP (FI) 2006-02-08 EP disclosed
US-6875775-B2 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD (FI) 2005-04-05 US disclosed
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators HORMOS MEDICAL OY LTD. 2003-12-04 US disclosed
US-6576645-B1 Such as 3-(4-chloro-1-(4-(2-(2-hydroxyethoxy)ethoxy)phenyl)--2-phenylbut-1 -enyl)phenol; producing tissue specific estro-genic and/or antiestrogenic effect HORMOS MEDICAL OY LTD (FI) 2003-06-10 US disclosed
EP-1235776-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS Hormos Medical Corporation (FI) 2002-09-04 EP disclosed
WO-2001036360-A1 TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS HORMOS MEDICAL CORPORATION (FI) 2001-05-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225130-A1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators ESR2, ESR1, GPER1 PKM 3466/4885NPC1 1166/4885STS 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.